Mediplantex National Pharmaceutical JSC (HNX:MED)

HNX:MED Balance Sheet

Financials in millions VND. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Jan 1, 2025	Jan 1, 2024	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	19,592	24,401	42,611	43,534	81,183	46,107
Short-Term Investments	11,700	6,700	12,000	20,000	92,400	48,400
Cash & Short-Term Investments	31,292	31,101	54,611	63,534	173,583	94,507
Cash Growth	-13.77%	-43.05%	-14.04%	-63.40%	83.67%	-12.15%
Accounts Receivable	40,607	39,366	66,896	90,917	127,297	113,221
Other Receivables	391.51	386.08	2,278	2,776	12,614	20,472
Receivables	40,999	39,752	69,174	93,693	139,911	133,694
Inventory	85,649	93,210	87,540	102,920	102,221	87,933
Prepaid Expenses	-	111.33	239.81	213.21	38.92	41.71
Other Current Assets	37,222	40,788	41,516	40,509	42,719	25,935
Total Current Assets	195,162	204,963	253,081	300,868	458,474	342,110
Property, Plant & Equipment	210,675	212,680	212,121	214,196	181,186	109,257
Other Intangible Assets	9.9	11.76	19.18	26.61	34.03	-
Other Long-Term Assets	57,170	39,663	38,534	40,152	58,793	42,271
Total Assets	463,017	457,317	503,755	555,243	698,487	493,638

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Jan 1, 2025	Jan 1, 2024	Dec 31, 2022	Dec 31, 2021
Accounts Payable	41,172	55,196	77,962	74,430	84,885	41,394
Accrued Expenses	12,694	16,025	14,827	15,950	14,771	8,501
Short-Term Debt	48,371	33,914	27,787	64,463	90,835	68,595
Current Income Taxes Payable	1,642	2,375	948.94	651.91	2,393	1,430
Current Unearned Revenue	16,101	228.6	219	29,637	-	-
Other Current Liabilities	2,827	18,267	51,149	42,914	183,602	207,937
Total Current Liabilities	122,808	126,006	172,892	228,046	376,486	327,857
Total Liabilities	122,808	126,006	172,892	228,046	376,486	327,857

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Jan 1, 2025	Jan 1, 2024	Dec 31, 2022	Dec 31, 2021
Common Stock	124,100	124,100	124,100	124,100	124,100	62,801
Additional Paid-In Capital	121,230	121,230	121,230	121,230	121,230	29,425
Retained Earnings	94,879	85,981	85,533	81,867	76,671	73,536
Comprehensive Income & Other	-	-	-	-	-	18.33
Shareholders' Equity	340,209	331,311	330,863	327,197	322,002	165,780
Total Liabilities & Equity	463,017	457,317	503,755	555,243	698,487	493,638

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Jan 1, 2025	Jan 1, 2024	Dec 31, 2022	Dec 31, 2021
Total Debt	48,371	33,914	27,787	64,463	90,835	68,595
Net Cash (Debt)	-17,080	-2,813	26,824	-929.58	82,748	25,912
Net Cash Growth	-	-	-	-	219.34%	-3.94%
Net Cash Per Share	-1376.09	-226.65	2161.51	-74.91	8813.28	4128.39
Filing Date Shares Outstanding	12.41	12.41	12.41	12.43	12.41	6.28
Total Common Shares Outstanding	12.41	12.41	12.41	12.43	12.41	6.28
Working Capital	72,354	78,957	80,189	72,822	81,988	14,253
Book Value Per Share	27414.10	26697.14	26661.01	26331.15	25946.94	26397.75
Tangible Book Value	340,199	331,300	330,844	327,170	321,968	165,780
Tangible Book Value Per Share	27413.31	26696.19	26659.47	26329.01	25944.20	26397.75
Buildings	47,111	47,111	47,111	47,111	-	-
Machinery	112,287	111,843	107,117	105,558	-	-
Construction In Progress	181,441	180,451	177,699	173,769	130,085	67,159

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 2, 2026

Data Sources Report a data error